155 completed, 11 unknown, 4 terminated, 3 active not recruiting. 101 Phase 3, 31 Phase 2, 21 Phase 4, 10 Phase 1, 6 Not applicable.
Follow Haemophilus Infections: new trials by email Literature Review of Haemophilus Infections trials Research Report on Haemophilus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
| Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo) - Haemophilus Influenzae, Haemophilus Influenzae Type a | Phase 2 | Active not recruiting | InventVacc Biologicals Inc. | 47 | 2026-04-29 | 2026-08-03 |
| Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP) - Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis | Phase 1 | Recruiting | CanSino Biologics Inc. | 260 | 2025-12-19 | 2025-12-31 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management Susceptibility to AMC, Susceptibilty to 3GC - Severe Community-acquired Pneumonia | Completed | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 104 | 2025-03-01 | 2026-07-07 | |
| Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine - Haemophilus Influenzae Type B Infection | Phase 1 | Active not recruiting | CanSino Biologics Inc. | 160 | 2024-11-15 | 2026-08-06 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine - Pertussis, Diphtheria | Not applicable | Unknown | Jiangsu Province Centers for Disease Control and Prevention | 785 | 2024-09-05 | 2024-09-20 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study) Vaxelis, PedvaxHIB - Haemophilus Influenzae Type B Infection | Phase 4 | Completed | Johns Hopkins Bloomberg School of Public Health | 333 | 2022-01-27 | 2024-06-24 |
| A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers DTPa-HBV-IPV/Hib, DTaP5-HBV-IPV-Hib, Pneumococcal 13-valent conjugate vaccine - Diphtheria | Phase 4 | Completed | GlaxoSmithKline | 500 | 2021-05-26 | 2024-08-27 |
| Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b Vaccine for the prevention of infections caused by Haemophilus influenza type b, Placebo - Haemophilus Influenzae Infection, Vaccines | Phase 1 | Completed | St. Petersburg Research Institute of Vaccines and Sera | 60 | 2020-01-14 | 2022-06-02 |
| Variations in the Composition of Respiratory Microbiota DNA extraction and 16S rRNA sequencing - Asthma | Completed | Applied Science Private University | 54 | 2019-12-01 | 2021-02-10 | |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| A Phase IV Study to Assess the Safety of EupentaTM Inj Eupenta Inj. - Hepatitis B, Diphtheria | Phase 4 | Unknown | LG Chem | 3000 | 2019-09-23 | 2019-08-14 |
| Confirmatory Study of BK1310 in Healthy Infants DPT-IPV-Hib, Hib vaccine, DPT-IPV - Tetanus, Diphtheria | Phase 3 | Completed | Tanabe Pharma Corporation | 267 | 2019-04-01 | 2026-01-06 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Evaluation of an Infant Immunization Encouragement Program in Nigeria All Babies Are Equal Initiative (conditional cash transfer program) - Tuberculosis, Diphtheria | Not applicable | Completed | GiveWell | 5187 | 2018-07-01 | 2020-03-31 |
| The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval - Diphtheria, Tetanus | Not applicable | Completed | Vabiotech | 222 | 2018-03-01 | 2019-05-03 |
| Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan SMS messages and automated calls - Tuberculosis, Polio | Not applicable | Unknown | Aga Khan University | 3850 | 2018-01-01 | 2017-11-17 |
Showing 20 of 177. Sign in to see all of them.
Diphtheria (107) · Tetanus (106) · Hepatitis B (82) · Poliomyelitis (71) · Whooping Cough (71) · Streptococcal Infections (11) · Measles (8) · Virus Diseases (7) · Infections (5) · Meningococcal Infections (5) · Mumps (5) · Rubella (5) · Bacterial Infections (4) · Chickenpox (4)
Bacterial Infections and Mycoses (177) · Pasteurellaceae Infections (177) · Gram-Negative Bacterial Infections (176) · Bacterial Infections (173) · Infections (172) · Gram-Positive Bacterial Infections (122) · Actinomycetales Infections (107) · Corynebacterium Infections (107) · Clostridium Infections (106) · Virus Diseases (101) · DNA Virus Infections (85) · Blood-Borne Infections (83) · Communicable Diseases (83) · Digestive System Diseases (83) · Hepadnaviridae Infections (82)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (30) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (15) · Heptavalent Pneumococcal Conjugate Vaccine (14) · Hiberix (14) · 13-valent pneumococcal vaccine (12) · Vaccines (12) · Pentavac (10) · Tetanus Toxoid (10) · pentacel (10) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (8) · PHiD-CV vaccine (8) · Diphtheria-Tetanus-acellular Pertussis Vaccines (7) · PEDIARIX (7) · DTaP-IPV-HB-PRP-T vaccine (6) · HibTITER protein, Haemophilus influenzae (6)
GlaxoSmithKline (82) · Sanofi Pasteur, a Sanofi Company (26) · Sanofi (10) · Novartis Vaccines (8) · LG Chem (7) · Tanabe Pharma Corporation (5) · Merck Sharp & Dohme LLC (4) · Crucell Holland BV (3) · Shantha Biotechnics Limited (3) · CanSino Biologics Inc. (2) · Centers for Disease Control and Prevention (2) · Forest Laboratories (2) · Johns Hopkins Bloomberg School of Public Health (2) · MCM Vaccines B.V. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
United States (23) · China (17) · Philippines (17) · Germany (14) · Finland (11) · Poland (11) · India (9) · Spain (9) · Thailand (8) · Canada (7) · Japan (6) · Mexico (6) · South Korea (6) · Sweden (6) · Argentina (5)
Raman Rao, MD (3) · Maria RZ Capeding, MD (2) · Abdul M Kazi, MBBS,MPH (1) · Aila Kristo, MD (1) · Alison Connor, PhD (1) · Anna Marttila, MD (1) · Anne Fiquet, MD (1) · Dagmar Dilloo, MD, PhD (1) · Daniel C Ehlman, MPH (1)
PMID 17716936, PMID 21482570, PMID 22327493, PMID 23357290, PMID 23964690, PMID 25487791, PMID 26702925, PMID 28340322, PMID 30597021, PMID 34922058, PMID 34986178, PMID 17090650, PMID 17321311, PMID 17545184, PMID 17699835, PMID 18086100, PMID 18463125, PMID 18532873, PMID 19117896, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19571722, PMID 19936044, PMID 20370483, PMID 20657177, PMID 20950456, PMID 20955461, PMID 21216000, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21372751, PMID 21482566, PMID 21482568, PMID 21807056, PMID 21875633, PMID 22001281, PMID 22157567, PMID 22210632, PMID 22273029, PMID 22349525, PMID 22531237, PMID 22691430, PMID 23158882, PMID 23241989, PMID 23340564, PMID 23966556, PMID 24173029, PMID 24176498
2008 (3), 2009 (2), 2014 (1), 2015 (1), 2016 (1), 2019 (1)